- Home
- KIM vs NBIX Comparison
KIM vs NBIX Comparison
Compare KIM & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KIM | NBIX |
|---|---|---|
| Founded | 1958 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 15.2B |
| IPO Year | 1991 | 1996 |
Fundamental Metrics
Financial Performance| Metric | KIM | NBIX |
|---|---|---|
| Price | $20.43 | $141.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 21 |
| Target Price | $24.17 | ★ $176.19 |
| AVG Volume (30 Days) | ★ 4.8M | 977.3K |
| Earning Date | 10-30-2025 | 02-05-2026 |
| Dividend Yield | ★ 5.09% | N/A |
| EPS Growth | ★ 57.13 | 12.44 |
| EPS | 0.83 | ★ 4.19 |
| Revenue | $2,123,057,000.00 | ★ $2,682,700,000.00 |
| Revenue This Year | $5.64 | $23.76 |
| Revenue Next Year | $3.02 | $18.01 |
| P/E Ratio | ★ $24.59 | $33.80 |
| Revenue Growth | 8.14 | ★ 19.61 |
| 52 Week Low | $17.93 | $84.23 |
| 52 Week High | $24.62 | $160.18 |
Technical Indicators
Market Signals| Indicator | KIM | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 50.51 | 38.05 |
| Support Level | $20.05 | $151.09 |
| Resistance Level | $20.59 | $155.55 |
| Average True Range (ATR) | 0.30 | 4.40 |
| MACD | 0.06 | -1.45 |
| Stochastic Oscillator | 71.47 | 2.53 |
Price Performance
Historical ComparisonAbout KIM Kimco Realty Corporation (HC)
One of the oldest real estate investment trusts in the United States, Kimco Realty owns interests in 567 shopping centers throughout major markets in the US, representing roughly 101 million square feet.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.